In-Cell-Art is a biopharmaceutical company
specializing in the preclinical and pharmaceutical development of nanocarriers named Nanotaxi® for macromolecular drugs. Its founder and research team, which includes a Nobel Laureate, have designed new classes of vectors that are organized on a nanometric scale, which enables them to cross the cell barrier efficiently and safely.
More From Us
In-Cell-Art publishes in the ACS Journal of Medicinal Chemistry new ionizable lipids that display "universal" delivery properties for mRNA, DNA and siRNA (J. Med. Chem. 2016, 59 (7), 3046-3062).
ICAntibodies™, the discovery of next-generation therapeutic antibodies
Production of the new "solution" for DNA or RNA vaccines
The “solutions” for your all transfections
Get the molecule you want with our chemical synthesis platform
mRNA Destination™, a novel technology for therapeutic protein production